$CLNN
Clene Inc. Stock $clnn

$clnn Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000095017022008241 Filed on May 09, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021 Q1
Revenue	$30.00K	$199.0K	$213.0K
YoY Change	-85.92%	-5.24%	204.29%
Cost Of Revenue	$0.00	-$523.0K	$240.0K
YoY Change	-100.0%	-5330.0%	300.0%
Gross Profit	$30.00K	$722.0K	-$30.00K
YoY Change	-200.0%	3510.0%	-400.0%
Gross Profit Margin	100.0%	362.81%	-14.08%
Selling, General & Admin	$4.757M	$5.257M	$5.190M
YoY Change	-8.34%	24.87%	540.74%
% of Gross Profit	15856.67%	728.12%
Research & Development	$8.580M	$9.323M	$6.275M
YoY Change	36.73%	136.03%	109.17%
% of Gross Profit	28600.0%	1291.27%
Depreciation & Amortization	$195.0K	$221.0K	$244.0K
YoY Change	-20.08%	-76.98%	10.91%
% of Gross Profit	650.0%	30.61%
Operating Expenses	$13.37M	$14.78M	$11.91M
YoY Change	12.24%	-26.54%	196.96%
Operating Profit	-$13.34M	-$14.06M	-$11.70M
YoY Change	14.03%	-30.06%	192.38%
Interest Expense	$782.0K	$15.51M	$551.0K
YoY Change	41.92%	20.87%	-1202.0%
% of Operating Profit
Other Income/Expense, Net	-$18.00K	$2.757M	-$28.13M
YoY Change	-99.94%	-124.38%	-25675.45%
Pretax Income	-$13.35M	$4.208M	-$39.83M
YoY Change	-66.47%	-122.87%	910.86%
Income Tax	$0.00	-$215.0K	-$72.00K
% Of Pretax Income		-5.11%
Net Earnings	-$13.35M	$4.423M	-$39.76M
YoY Change	-66.41%	-123.51%	908.78%
Net Earnings / Revenue	-44513.33%	2222.61%	-18664.79%
Basic Earnings Per Share	-$0.21
Diluted Earnings Per Share	-$212.5K	$70.98K	-$655.3K
COMMON SHARES
Basic Shares Outstanding	63.14M
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q1	2021 Q4	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$36.52M	$50.29M	$48.04M
YoY Change	-23.99%	-15.17%	14457.58%
Cash & Equivalents	$12.90M	$50.29M	$48.04M
Short-Term Investments	$23.59M
Other Short-Term Assets	$3.978M	$2.641M	$2.420M
YoY Change	64.38%	95.63%	7966.67%
Inventory	$38.00K	$41.00K	$360.0K
Prepaid Expenses	$5.895M	$4.205M
Receivables		$49.00K	$120.0K
Other Receivables	$1.917M	$1.564M	$2.410M
Total Short-Term Assets	$42.45M	$54.58M	$53.34M
YoY Change	-20.42%	-13.35%	14716.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.914M	$5.172M	$5.190M
YoY Change	13.95%	22.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$58.00K	$58.00K
YoY Change
Total Long-Term Assets	$10.91M	$8.480M	$5.190M
YoY Change	110.25%	61.4%	-89.39%
TOTAL ASSETS
Total Short-Term Assets	$42.45M	$54.58M	$53.34M
Total Long-Term Assets	$10.91M	$8.480M	$5.190M
Total Assets	$53.36M	$63.06M	$58.53M
YoY Change	-8.83%	-7.59%	18.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.313M	$1.923M	$740.0K
YoY Change	347.7%	71.09%
Accrued Expenses	$1.541M	$3.610M	$2.930M
YoY Change	-47.41%	-8.84%	1853.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$139.0K	$146.0K	$140.0K
YoY Change	-0.71%	-23.16%
Total Short-Term Liabilities	$5.466M	$6.026M	$4.090M
YoY Change	33.64%	-48.35%	107.61%
LONG-TERM LIABILITIES
Long-Term Debt	$19.44M	$19.18M	$2.050M
YoY Change	848.24%	792.05%
Other Long-Term Liabilities	$26.44M	$25.26M	$88.25M
YoY Change	-70.04%	-53.06%	4696.2%
Total Long-Term Liabilities	$45.88M	$44.44M	$90.30M
YoY Change	-49.19%	-20.6%	4807.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.466M	$6.026M	$4.090M
Total Long-Term Liabilities	$45.88M	$44.44M	$90.30M
Total Liabilities	$51.34M	$50.47M	$94.61M
YoY Change	-45.73%	-25.68%	2383.2%
SHAREHOLDERS EQUITY
Retained Earnings	-$176.7M	-$163.3M
YoY Change		6.34%
Common Stock	$6.000K	$6.000K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.017M	$12.60M	-$36.08M
YoY Change
Total Liabilities & Shareholders Equity	$53.36M	$63.06M	$58.53M
YoY Change	-8.83%	-7.59%	18.75%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021 Q1
OPERATING ACTIVITIES
Net Income	-$13.35M	$4.423M	-$39.76M
YoY Change	-66.41%	-123.51%	908.78%
Depreciation, Depletion And Amortization	$195.0K	$221.0K	$244.0K
YoY Change	-20.08%	-76.98%	10.91%
Cash From Operating Activities	-$13.10M	-$9.606M	-$9.200M
YoY Change	42.39%	-47.02%	183.08%
INVESTING ACTIVITIES
Capital Expenditures	$936.0K	-$671.0K	$203.0K
YoY Change	361.08%	72.05%	-1115.0%
Acquisitions
YoY Change
Other Investing Activities	-$23.59M
YoY Change
Cash From Investing Activities	-$24.52M	-$671.0K	-$203.0K
YoY Change	11979.8%	72.05%	915.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	235.0K	-18.00K	-1.896M
YoY Change	-112.39%	-100.03%	-222.32%
NET CHANGE
Cash From Operating Activities	-13.10M	-9.606M	-9.200M
Cash From Investing Activities	-24.52M	-671.0K	-203.0K
Cash From Financing Activities	235.0K	-18.00K	-1.896M
Net Change In Cash	-37.36M	-10.30M	-11.23M
YoY Change	232.54%	-120.51%	553.14%
FREE CASH FLOW
Cash From Operating Activities	-$13.10M	-$9.606M	-$9.200M
Capital Expenditures	$936.0K	-$671.0K	$203.0K
Free Cash Flow	-$14.04M	-$8.935M	-$9.403M
YoY Change	49.27%	-49.63%	191.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001822791
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	01-39834
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	CLENE INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-2828339
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	6550 South Millrock Drive
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite G50
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84121
CY2022Q1	dei	City Area Code CityAreaCode	801
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	676-9695
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2022Q1	dei	Trading Symbol TradingSymbol	CLNN
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	63256545
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12930000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50288000
CY2022Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	23586000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	49000
CY2022Q1	us-gaap	Inventory Net InventoryNet	38000
CY2021Q4	us-gaap	Inventory Net InventoryNet	41000
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3393000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1968000
CY2022Q1	clnn	Metals To Be Used In Research And Development MetalsToBeUsedInResearchAndDevelopment	2502000
CY2021Q4	clnn	Metals To Be Used In Research And Development MetalsToBeUsedInResearchAndDevelopment	2237000
CY2022Q1	us-gaap	Assets Current AssetsCurrent	42449000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	54583000
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	58000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	58000
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4940000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3250000
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5914000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5172000
CY2022Q1	us-gaap	Assets Assets	53361000
CY2021Q4	us-gaap	Assets Assets	63063000
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3313000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1923000
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1541000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3610000
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	473000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	347000
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	139000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	146000
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5466000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6026000
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5766000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4370000
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	72000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	97000
CY2022Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	14712000
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	14484000
CY2022Q1	clnn	Convertible Note Payable ConvertibleNotePayable	4655000
CY2021Q4	clnn	Convertible Note Payable ConvertibleNotePayable	4598000
CY2022Q1	clnn	Common Stock Warrant Liability CommonStockWarrantLiability	187000
CY2021Q4	clnn	Common Stock Warrant Liability CommonStockWarrantLiability	474000
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	18157000
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	18100000
CY2022Q1	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	2329000
CY2021Q4	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	2317000
CY2022Q1	us-gaap	Liabilities Liabilities	51344000
CY2021Q4	us-gaap	Liabilities Liabilities	50466000
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63246545
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63246545
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62312097
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62312097
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	6000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6000
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	178433000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	175659000
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176655000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163301000
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	233000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	233000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	2017000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	12597000
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53361000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63063000
CY2022Q1	us-gaap	Revenues Revenues	30000
CY2021Q1	us-gaap	Revenues Revenues	213000
CY2022Q1	clnn	Costs Of Revenue CostsOfRevenue	0
CY2021Q1	clnn	Costs Of Revenue CostsOfRevenue	243000
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8580000
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6275000
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4786000
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5390000
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	11908000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13336000
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11695000
CY2022Q1	us-gaap	Interest Expense InterestExpense	782000
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	13366000
CY2021Q1	us-gaap	Interest Expense InterestExpense	551000
CY2022Q1	clnn	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	0
CY2021Q1	clnn	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	647000
CY2022Q1	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	420000
CY2021Q1	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0
CY2022Q1	clnn	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	-18000
CY2021Q1	clnn	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	0
CY2022Q1	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	-57000
CY2021Q1	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	-25610000
CY2022Q1	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	-12000
CY2021Q1	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	-2961000
CY2022Q1	clnn	Australia Research And Development Credit AustraliaResearchAndDevelopmentCredit	-299000
CY2021Q1	clnn	Australia Research And Development Credit AustraliaResearchAndDevelopmentCredit	-339000
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	132000
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18000
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-28133000
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13354000
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39828000
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-72000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13354000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-39756000
CY2022Q1	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	50000
CY2021Q1	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	0
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	50000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	24000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0
CY2021Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-24000
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13354000
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39732000
CY2022Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
CY2022Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62852863
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60670932
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	12597000
CY2022Q1	clnn	Reclassification Of Common Stock Warrant Liability To Permanent Equity ReclassificationOfCommonStockWarrantLiabilityToPermanentEquity	305000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	267000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2202000
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-50000
CY2022Q1	clnn	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	50000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-13354000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	2017000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	341000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3265000
CY2021Q1	clnn	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	24000
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-39756000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-36076000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13354000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-39756000
CY2022Q1	us-gaap	Depreciation Depreciation	195000
CY2021Q1	us-gaap	Depreciation Depreciation	244000
CY2022Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	52000
CY2021Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	22000
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	18000
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2022Q1	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	-57000
CY2021Q1	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	-25610000
CY2022Q1	clnn	Changes In Fair Value Of Initial Shareholders Contingent Earnout ChangesInFairValueOfInitialShareholdersContingentEarnout	-12000
CY2021Q1	clnn	Changes In Fair Value Of Initial Shareholders Contingent Earnout ChangesInFairValueOfInitialShareholdersContingentEarnout	-2961000
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2202000
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3265000
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	647000
CY2022Q1	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	420000
CY2021Q1	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	227000
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	45000
CY2021Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	543000
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-49000
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	103000
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3000
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	164000
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1691000
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1321000
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1389000
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	161000
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2069000
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	125000
CY2021Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	46000
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	201000
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-55000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13084000
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9161000
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	23586000
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	936000
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	203000
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-24522000
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-203000
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	267000
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	50000
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	32000
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	45000
CY2021Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1901000
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	235000
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1896000
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	13000
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	26000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-37358000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11234000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50346000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59275000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12988000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48041000
CY2022Q1	us-gaap	Cash Cash	12930000
CY2021Q1	us-gaap	Cash Cash	48041000
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	58000
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	0
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12988000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48041000
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2343000
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2022Q1	clnn	Lease Liability Settled Through Termination Of Lease LeaseLiabilitySettledThroughTerminationOfLease	602000
CY2021Q1	clnn	Lease Liability Settled Through Termination Of Lease LeaseLiabilitySettledThroughTerminationOfLease	0
CY2022Q1	clnn	Reclassification Of Common Stock Warrant Liability To Permanent Equity ReclassificationOfCommonStockWarrantLiabilityToPermanentEquity	305000
CY2021Q1	clnn	Reclassification Of Common Stock Warrant Liability To Permanent Equity ReclassificationOfCommonStockWarrantLiabilityToPermanentEquity	0
CY2022Q1	clnn	Cash Paid For Interest Expense CashPaidForInterestExpense	493000
CY2021Q1	clnn	Cash Paid For Interest Expense CashPaidForInterestExpense	8000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13300000
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11700000
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176700000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163300000
CY2022Q1	clnn	Cash Cash Equivalents Restricted Cash And Marketable Securities CashCashEquivalentsRestrictedCashAndMarketableSecurities	36600000
CY2021Q4	clnn	Cash Cash Equivalents Restricted Cash And Marketable Securities CashCashEquivalentsRestrictedCashAndMarketableSecurities	50300000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13100000
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9200000
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	100000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	100000
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosure of contingent assets and liabilities, and the reported amounts of expenses. We base our estimates on historical experience and various other assumptions that we believe to be reasonable. Actual results may differ from those estimates or assumptions. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience, and any changes in estimates will be recorded in future periods as they develop.</span></p>
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject us to significant concentrations of credit risk consist primarily of cash. Our cash is mainly held in financial institutions. Amounts on deposit may at times exceed federally insured limits. We have not experienced any losses on our deposits of cash and do not believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p>
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12900000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50300000
CY2022Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	7400000
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0
CY2022Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	24000
CY2022Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	14000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	26000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	15000
CY2022Q1	clnn	Grant Funding Recognized On Conditional Grants GrantFundingRecognizedOnConditionalGrants	0
CY2021Q1	clnn	Grant Funding Recognized On Conditional Grants GrantFundingRecognizedOnConditionalGrants	200000
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2020Q4	clnn	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	9400000
CY2020Q4	clnn	Net Proceeds From Reverse Recapitalization NetProceedsFromReverseRecapitalization	3500000
CY2020Q4	clnn	Shares Issued For Payment Of Offering Costs SharesIssuedForPaymentOfOfferingCosts	644164
CY2022Q1	clnn	Clene Nanomedicine Contingent Earn Out Milestone1 Shares CleneNanomedicineContingentEarnOutMilestone1Shares	3333333
CY2022Q1	clnn	Clene Nanomedicine Contingent Earnout Milestone1 Price CleneNanomedicineContingentEarnoutMilestone1Price	15.00
CY2022Q1	clnn	Clene Nanomedicine Contingent Earnout Milestone2 Shares CleneNanomedicineContingentEarnoutMilestone2Shares	2500000
CY2022Q1	clnn	Clene Nanomedicine Contingent Earnout Milestone2 Price CleneNanomedicineContingentEarnoutMilestone2Price	20.00
CY2022Q1	clnn	Clene Nanomedicine Contingent Earnout Milestone3 Shares CleneNanomedicineContingentEarnoutMilestone3Shares	2500000
CY2022Q1	clnn	Total Clene Nanomedicine Contingent Earnout Shares TotalCleneNanomedicineContingentEarnoutShares	8346185
CY2022Q1	clnn	Initial Shareholders Contingent Earnout Milestone One Shares InitialShareholdersContingentEarnoutMilestoneOneShares	375000
CY2022Q1	clnn	Initial Shareholders Contingent Earnout Milestone2 Shares InitialShareholdersContingentEarnoutMilestone2Shares	375000
CY2021Q4	clnn	Clene Nanomedicine Contingent Earnout Milestone Three Shares Cancelled CleneNanomedicineContingentEarnoutMilestoneThreeSharesCancelled	2503851
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	23636000
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	50000
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	23586000
CY2022Q1	clnn	Debt Securities Available For Sale Maturity Period DebtSecuritiesAvailableForSaleMaturityPeriod	P1Y
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0
CY2022Q1	clnn	Australia Research And Development Credit Receivable AustraliaResearchAndDevelopmentCreditReceivable	-1917000
CY2021Q4	clnn	Australia Research And Development Credit Receivable AustraliaResearchAndDevelopmentCreditReceivable	-1564000
CY2022Q1	clnn	Cro Prepayments CROPrepayments	103000
CY2021Q4	clnn	Cro Prepayments CROPrepayments	194000
CY2022Q1	clnn	Directors Officers Insurance DirectorsOfficersInsurance	997000
CY2021Q4	clnn	Directors Officers Insurance DirectorsOfficersInsurance	41000
CY2022Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	376000
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	169000
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3393000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1968000
CY2022Q1	clnn	Metals To Be Used In Research And Development MetalsToBeUsedInResearchAndDevelopment	2502000
CY2021Q4	clnn	Metals To Be Used In Research And Development MetalsToBeUsedInResearchAndDevelopment	2237000
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5895000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4205000
CY2022Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	3383000
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	3327000
CY2022Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	147000
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	147000
CY2022Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	3949000
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	3943000
CY2022Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	2955000
CY2021Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	2052000
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10434000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9469000
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4520000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4297000
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5914000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5172000
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	0
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	30000
CY2022Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	733000
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2049000
CY2022Q1	clnn	Accrued Cro Fees AccruedCROFees	82000
CY2021Q4	clnn	Accrued Cro Fees AccruedCROFees	718000
CY2022Q1	clnn	Deferred Grant Funds DeferredGrantFunds	520000
CY2021Q4	clnn	Deferred Grant Funds DeferredGrantFunds	520000
CY2022Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	0
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	33000
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	206000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	260000
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1541000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3610000
CY2021Q3	clnn	Operating Leases Rightof Use Assets OperatingLeasesRightofUseAssets	2400000
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2400000
CY2021Q3	us-gaap	Incentive To Lessee IncentiveToLessee	1000000.0
CY2022Q1	clnn	Lease Incentive Recorded Construction In Progress LeaseIncentiveRecordedConstructionInProgress	800000
CY2021Q4	clnn	Lease Incentive Recorded Construction In Progress LeaseIncentiveRecordedConstructionInProgress	500000
CY2022Q1	us-gaap	Lessor Operating Lease Description LessorOperatingLeaseDescription	The lease has an initial ten-year term and provides us the right and option to extend or renew for two periods of five years each. In accordance with ASC 842, Leases, the payments to be made in option periods have not been recognized as part of the right-of-use asset or lease liability because we do not assess the exercise of the option to be reasonably certain.
CY2022Q1	clnn	Operating Leases Rightof Use Assets OperatingLeasesRightofUseAssets	2300000
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2300000
CY2022Q1	clnn	Terminated Right Of Use Asset TerminatedRightOfUseAsset	600000
CY2022Q1	clnn	Terminated Operating Lease Liability TerminatedOperatingLeaseLiability	1000000.0
CY2022Q1	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	400000
CY2022Q1	clnn	Operating Lease Obligations Weighted Average Interest Rate OperatingLeaseObligationsWeightedAverageInterestRate	0.096
CY2021Q4	clnn	Operating Lease Obligations Weighted Average Interest Rate OperatingLeaseObligationsWeightedAverageInterestRate	0.096
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y1M6D
CY2021Q1	us-gaap	Lease Cost LeaseCost	196000
CY2022Q1	clnn	Finance Lease Laboratory Equipment Gross FinanceLeaseLaboratoryEquipmentGross	408000
CY2021Q4	clnn	Finance Lease Laboratory Equipment Gross FinanceLeaseLaboratoryEquipmentGross	408000
CY2022Q1	clnn	Finance Lease Work In Process Gross FinanceLeaseWorkInProcessGross	228000
CY2021Q4	clnn	Finance Lease Work In Process Gross FinanceLeaseWorkInProcessGross	228000
CY2022Q1	clnn	Finance Lease Liability Gross FinanceLeaseLiabilityGross	636000
CY2021Q4	clnn	Finance Lease Liability Gross FinanceLeaseLiabilityGross	636000
CY2022Q1	clnn	Accumulated Depreciation Depletion And Amortization Leases AccumulatedDepreciationDepletionAndAmortizationLeases	-265000
CY2021Q4	clnn	Accumulated Depreciation Depletion And Amortization Leases AccumulatedDepreciationDepletionAndAmortizationLeases	-244000
CY2022Q1	clnn	Finance Lease Liability Net FinanceLeaseLiabilityNet	371000
CY2021Q4	clnn	Finance Lease Liability Net FinanceLeaseLiabilityNet	392000
CY2022Q1	clnn	Finance Lease Obligations Weightedaverage Interest Rate FinanceLeaseObligationsWeightedaverageInterestRate	0.089
CY2021Q4	clnn	Finance Lease Obligations Weightedaverage Interest Rate FinanceLeaseObligationsWeightedaverageInterestRate	0.088
CY2022Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M12D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M24D
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	20000
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	37000
CY2022Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	5000
CY2021Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	8000
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	230000
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	70000
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2021Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	62000
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	65000
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	19000
CY2022Q1	us-gaap	Lease Cost LeaseCost	320000
CY2022Q1	clnn	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	-295000
CY2021Q1	clnn	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	-151000
CY2022Q1	clnn	Operating Cash Flows From Finance Leases OperatingCashFlowsFromFinanceLeases	-5000
CY2021Q1	clnn	Operating Cash Flows From Finance Leases OperatingCashFlowsFromFinanceLeases	-8000
CY2022Q1	clnn	Finance Cash Flows From Finance Leases FinanceCashFlowsFromFinanceLeases	-32000
CY2021Q1	clnn	Finance Cash Flows From Finance Leases FinanceCashFlowsFromFinanceLeases	-45000
CY2022Q1	clnn	Total Term Loans TotalTermLoans	20748000
CY2021Q4	clnn	Total Term Loans TotalTermLoans	20736000
CY2022Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1381000
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1654000
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-4655000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-4598000
CY2022Q1	clnn	Total Notes Payable And Convertible Notes Payable TotalNotesPayableAndConvertibleNotesPayable	14712000
CY2021	clnn	Total Notes Payable And Convertible Notes Payable TotalNotesPayableAndConvertibleNotesPayable	14484000
CY2022Q1	us-gaap	Debt Instrument Interest Rate Basis For Effective Rate DebtInstrumentInterestRateBasisForEffectiveRate	the effective interest rate was 15.71%.
CY2022Q1	clnn	Schedule Of Future Payments Net Of Unamortized Debt Discounts ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts	<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Future payments under the 2021 Avenue Loan, net of unamortized debt discounts, if Avenue does not exercise the Conversion Feature are as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.028%;"/> <td style="width:1.939%;"/> <td style="width:1.206%;"/> <td style="width:16.03%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021 Avenue Loan</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2022 (remainder)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6,667</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2024</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13,333</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Thereafter</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Subtotal of future principal payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">20,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Less unamortized debt discount associated with issuance date warrant fair value and financing costs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,381</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18,619</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table>
CY2022Q1	clnn	Debt Instrument Unamortized Discount Remainder Of Fiscal Year DebtInstrumentUnamortizedDiscountRemainderOfFiscalYear	0
CY2022Q1	clnn	Debt Instrument Unamortized Discount Year One DebtInstrumentUnamortizedDiscountYearOne	6667000
CY2022Q1	clnn	Debt Instrument Unamortized Discount Year Two DebtInstrumentUnamortizedDiscountYearTwo	13333000
CY2022Q1	clnn	Debt Instrument Thereafter DebtInstrumentThereafter	0
CY2022Q1	clnn	Future Principal Payments FuturePrincipalPayments	20000000
CY2022Q1	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	1381000
CY2022Q1	us-gaap	Debt Securities DebtSecurities	18619000
CY2022Q1	clnn	Number Of Shares Issuable NumberOfSharesIssuable	4477045
CY2021Q4	clnn	Number Of Shares Issuable NumberOfSharesIssuable	4477045
CY2022Q1	us-gaap	Shares Issued SharesIssued	2407500
CY2022Q1	clnn	Company Warrant Redemption Right CompanyWarrantRedemptionRight	We may redeem the outstanding warrants, in whole and not in part, at $0.01 per warrant if the last sales price of our Common Stock equals or exceeds $16.50 per share for any twenty trading days within a thirty-trading day period.
CY2022Q1	clnn	Warrant Redemption Price Per Share WarrantRedemptionPricePerShare	0.01
CY2022Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	16.50
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-12957000
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-38721000
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-397000
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1107000
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13354000
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39828000
CY2022Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2022Q1	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.03
CY2022Q1	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	4500000
CY2022Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000
CY2021Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2202000
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3265000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10395027
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.35
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M25D
CY2021Q4	clnn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue	21082000
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2492515
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.03
CY2022Q1	clnn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted	P9Y10M17D
CY2022Q1	clnn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted	0
CY2022Q1	clnn	Share Based Compensation Arrangement Number Of Options Exercised ShareBasedCompensationArrangementNumberOfOptionsExercised	934448
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.29
CY2022Q1	clnn	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue	3414000
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	8305
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.89
CY2022Q1	clnn	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11944789
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.52
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y1M13D
CY2022Q1	clnn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue	18931000
CY2022Q1	clnn	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber	5577405
CY2022Q1	clnn	Weighted Average Exercise Price Per Share Option Vested And Exercisable WeightedAverageExercisePricePerShareOptionVestedAndExercisable	1.38
CY2022Q1	clnn	Weighted Average Exercise Price Weighted Average Remaining Term Years Options Vested And Eexercisable Ending WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding	P4Y6M21D
CY2022Q1	clnn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Intrinsic Value Intrinsic Value Options Vested And Exercisable Ending ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding	16146000
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	11944789
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.52
CY2022Q1	clnn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1	P7Y1M13D
CY2022Q1	clnn	Intrinsic Value Stock Options Vested And Expected To Vest Intrinsic Value Options V IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV	18931000
CY2022Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2200000
CY2021Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	300000
CY2022Q1	clnn	Unrecognized Stockbased Compensation UnrecognizedStockbasedCompensation	21700000
CY2021	clnn	Unrecognized Stockbased Compensation UnrecognizedStockbasedCompensation	18300000
CY2022Q1	clnn	Sharebased Compensation Arrangement By Sharebased Payment Award Nonvestweighted Average Period Expected Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm	P3Y21D
CY2021	clnn	Sharebased Compensation Arrangement By Sharebased Payment Award Nonvestweighted Average Period Expected Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm	P3Y18D
CY2022Q1	clnn	Weighted Average Fair Values Of Options Granted weightedAverageFairValuesOfOptionsGranted	2.25
CY2021Q1	clnn	Weighted Average Fair Values Of Options Granted weightedAverageFairValuesOfOptionsGranted	6.55
CY2021Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	3000.0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0
CY2022Q1	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	748000
CY2022Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	187000
CY2022Q1	clnn	Clene Nanomedicine Contingent Earnout Fair Value Disclosure CleneNanomedicineContingentEarnoutFairValueDisclosure	18157000
CY2022Q1	clnn	Initial Shareholders Contingent Earnout Fair Value Disclosure InitialShareholdersContingentEarnoutFairValueDisclosure	2329000
CY2021Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	736000
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	474000
CY2021Q4	clnn	Clene Nanomedicine Contingent Earnout Fair Value Disclosure CleneNanomedicineContingentEarnoutFairValueDisclosure	18100000
CY2021Q4	clnn	Initial Shareholders Contingent Earnout Fair Value Disclosure InitialShareholdersContingentEarnoutFairValueDisclosure	2317000
CY2022Q1	clnn	Notes Payable Based On Closing Price NotesPayableBasedOnClosingPrice	3.94
CY2021	clnn	Notes Payable Based On Closing Price NotesPayableBasedOnClosingPrice	4.10
CY2022Q1	clnn	Fair Value Amortized Cost FairValueAmortizedCost	18600000
CY2022Q1	us-gaap	Notes Payable NotesPayable	13900000
CY2022Q1	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	4700000
CY2021	clnn	Fair Value Amortized Cost FairValueAmortizedCost	18300000
CY2021Q4	us-gaap	Notes Payable NotesPayable	13700000
CY2021	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	4600000
CY2022Q1	clnn	Fair Value Of Conversion Feature FairValueOfConversionFeature	700000
CY2021Q4	clnn	Fair Value Of Conversion Feature FairValueOfConversionFeature	800000
CY2022Q1	clnn	Changeinfairvaluewarrants Changeinfairvaluewarrants	18000
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.63
CY2022Q1	clnn	Avenue Warrant Share Issuable AvenueWarrantShareIssuable	115851
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	18200000
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	18100000
CY2022Q1	clnn	Gain Loss On Clene Nano Medicine Contingents Earnout GainLossOnCleneNanoMedicineContingentsEarnout	100000
CY2021Q1	clnn	Gain Loss On Clene Nano Medicine Contingents Earnout GainLossOnCleneNanoMedicineContingentsEarnout	25600000
CY2022Q1	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	2300000
CY2021Q4	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	2300000
CY2022Q1	clnn	Gain Loss On Initial Shareholders Contingents Earnout GainLossOnInitialShareholdersContingentsEarnout	12000
CY2021Q1	clnn	Gain Loss On Initial Shareholders Contingents Earnout GainLossOnInitialShareholdersContingentsEarnout	3000000.0
CY2022Q1	clnn	Convertible Notes Payables ConvertibleNotesPayables	482703
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	clnn	Preferred Stock Shares PreferredStockShares	1000000
CY2021	clnn	Preferred Stock Shares PreferredStockShares	1000000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	clnn	Issuance Of Common Stock Upon Reverse Recapitalization IssuanceOfCommonStockUponReverseRecapitalization	2239500
CY2020Q4	us-gaap	Share Price SharePrice	10.00
CY2020Q4	clnn	Net Proceeds NetProceeds	22200000
CY2022Q1	clnn	Private Placement Warrants Description PrivatePlacementWarrantsDescription	In addition, investors in the 2020 PIPE also received warrants (the “PIPE Warrants”) to purchase a number of shares equal to one-half (1/2) of the number of 2020 PIPE shares, totaling 1,119,750 shares of Common Stock, at $0.01 per share and subject to a 180-day holding period.
	clnn	Shares Issued Upon Exercise Of Warrants SharesIssuedUponExerciseOfWarrants	1119750
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	11198
CY2021Q2	clnn	Common Stock Shares Purchased CommonStockSharesPurchased	960540000
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63246545
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62312097
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13354000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-39756000
CY2022Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62852863
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60670932
CY2022Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
CY2021Q1	clnn	Convertible Notes Payables ConvertibleNotesPayables	0
CY2022Q1	clnn	Common Stock Warrants CommonStockWarrants	4477045
CY2021Q1	clnn	Common Stock Warrants CommonStockWarrants	4446613
CY2022Q1	clnn	Options To Purchase Common Stockin Shares OptionsToPurchaseCommonStockinShares	11944789
CY2021Q1	clnn	Options To Purchase Common Stockin Shares OptionsToPurchaseCommonStockinShares	7105801
CY2022Q1	clnn	Unvested Restricted Stock Awards Shares UnvestedRestrictedStockAwardsShares	914876
CY2021Q1	clnn	Unvested Restricted Stock Awards Shares UnvestedRestrictedStockAwardsShares	0
CY2022Q1	clnn	Chardan Unit Purchase Option Warrants ChardanUnitPurchaseOptionWarrants	0
CY2021Q1	clnn	Chardan Unit Purchase Option Warrants ChardanUnitPurchaseOptionWarrants	242000
CY2022Q1	clnn	Earnoutshares Earnoutshares	6592334
CY2021Q1	clnn	Earnoutshares Earnoutshares	9096185
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	24411747
CY2021Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	20890599
CY2018Q3	clnn	Exclusive Rights Intellectual Property Term ExclusiveRightsIntellectualPropertyTerm	P5Y
CY2018Q3	clnn	Related Party Transaction Royalty Fee Rate For Revenues RelatedPartyTransactionRoyaltyFeeRateForRevenues	0.03
CY2022Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0
CY2021Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	200000
CY2022Q1	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	23000
CY2021Q1	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	14000
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5914000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5172000
CY2022Q1	us-gaap	Revenues Revenues	30000
CY2021Q1	us-gaap	Revenues Revenues	213000
CY2022Q1	us-gaap	Depreciation Depreciation	195000
CY2021Q1	us-gaap	Depreciation Depreciation	244000
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2202000
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3265000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13336000
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11695000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13336000
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11695000
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18000
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-28133000
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13354000
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39828000
CY2022Q1	us-gaap	Assets Assets	53361000
CY2021Q4	us-gaap	Assets Assets	63063000
CY2022Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	936000
CY2021Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	203000

Files In Submission

Name	View Source	Status
0000950170-22-008241-index-headers.html	Edgar Link	pending
0000950170-22-008241-index.html	Edgar Link	pending
0000950170-22-008241.txt	Edgar Link	pending
0000950170-22-008241-xbrl.zip	Edgar Link	pending
clnn-20220331.htm	Edgar Link	pending
clnn-20220331.xsd	Edgar Link	pending
clnn-20220331_cal.xml	Edgar Link	unprocessable
clnn-20220331_def.xml	Edgar Link	unprocessable
clnn-20220331_htm.xml	Edgar Link	completed
clnn-20220331_lab.xml	Edgar Link	unprocessable
clnn-20220331_pre.xml	Edgar Link	unprocessable
clnn-ex31_1.htm	Edgar Link	pending
clnn-ex31_2.htm	Edgar Link	pending
clnn-ex32_1.htm	Edgar Link	pending
clnn-ex32_2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img180851459_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLNN
Clene Inc. Stock $clnn

2022 Q1 Form 10-Q Financial Statement

#000095017022008241 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLNN Clene Inc. Stock $clnn

2022 Q1 Form 10-Q Financial Statement

#000095017022008241 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLNN
Clene Inc. Stock $clnn